206 related articles for article (PubMed ID: 18563780)
1. Fighting cancer: from the bench to bedside using second generation cationic liposomal therapeutics.
Campbell RB; Ying B; Kuesters GM; Hemphill R
J Pharm Sci; 2009 Feb; 98(2):411-29. PubMed ID: 18563780
[TBL] [Abstract][Full Text] [Related]
2. Recent advances in tumor vasculature targeting using liposomal drug delivery systems.
Abu Lila AS; Ishida T; Kiwada H
Expert Opin Drug Deliv; 2009 Dec; 6(12):1297-309. PubMed ID: 19780711
[TBL] [Abstract][Full Text] [Related]
3. Targeting anticancer drugs to tumor vasculature using cationic liposomes.
Abu Lila AS; Ishida T; Kiwada H
Pharm Res; 2010 Jul; 27(7):1171-83. PubMed ID: 20333455
[TBL] [Abstract][Full Text] [Related]
4. Combination therapy with metronomic S-1 dosing and oxaliplatin-containing PEG-coated cationic liposomes in a murine colorectal tumor model: synergy or antagonism?
Abu Lila AS; Okada T; Doi Y; Ichihara M; Ishida T; Kiwada H
Int J Pharm; 2012 Apr; 426(1-2):263-270. PubMed ID: 22310465
[TBL] [Abstract][Full Text] [Related]
5. Oxaliplatin encapsulated in PEG-coated cationic liposomes induces significant tumor growth suppression via a dual-targeting approach in a murine solid tumor model.
Abu Lila AS; Kizuki S; Doi Y; Suzuki T; Ishida T; Kiwada H
J Control Release; 2009 Jul; 137(1):8-14. PubMed ID: 19285528
[TBL] [Abstract][Full Text] [Related]
6. Vascular targeting of doxorubicin using cationic liposomes.
Wu J; Lee A; Lu Y; Lee RJ
Int J Pharm; 2007 Jun; 337(1-2):329-35. PubMed ID: 17275230
[TBL] [Abstract][Full Text] [Related]
7. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
8. Characterization of cationic liposome formulations designed to exhibit extended plasma residence times and tumor vasculature targeting properties.
Ho EA; Ramsay E; Ginj M; Anantha M; Bregman I; Sy J; Woo J; Osooly-Talesh M; Yapp DT; Bally MB
J Pharm Sci; 2010 Jun; 99(6):2839-53. PubMed ID: 20091826
[TBL] [Abstract][Full Text] [Related]
9. Anti-angiogenic therapy via cationic liposome-mediated systemic siRNA delivery.
Tagami T; Suzuki T; Matsunaga M; Nakamura K; Moriyoshi N; Ishida T; Kiwada H
Int J Pharm; 2012 Jan; 422(1-2):280-9. PubMed ID: 22101286
[TBL] [Abstract][Full Text] [Related]
10. Oxaliplatin targeting to angiogenic vessels by PEGylated cationic liposomes suppresses the angiogenesis in a dorsal air sac mouse model.
Abu-Lila A; Suzuki T; Doi Y; Ishida T; Kiwada H
J Control Release; 2009 Feb; 134(1):18-25. PubMed ID: 19010364
[TBL] [Abstract][Full Text] [Related]
11. Development and characterization of magnetic cationic liposomes for targeting tumor microvasculature.
Dandamudi S; Campbell RB
Biochim Biophys Acta; 2007 Mar; 1768(3):427-38. PubMed ID: 17258172
[TBL] [Abstract][Full Text] [Related]
12. Sequential administration with oxaliplatin-containing PEG-coated cationic liposomes promotes a significant delivery of subsequent dose into murine solid tumor.
Abu Lila AS; Doi Y; Nakamura K; Ishida T; Kiwada H
J Control Release; 2010 Mar; 142(2):167-73. PubMed ID: 19861140
[TBL] [Abstract][Full Text] [Related]
13. Importance of the liposomal cationic lipid content and type in tumor vascular targeting: physicochemical characterization and in vitro studies using human primary and transformed endothelial cells.
Dabbas S; Kaushik RR; Dandamudi S; Kuesters GM; Campbell RB
Endothelium; 2008; 15(4):189-201. PubMed ID: 18663622
[TBL] [Abstract][Full Text] [Related]
14. Paclitaxel encapsulated in cationic liposomes diminishes tumor angiogenesis and melanoma growth in a "humanized" SCID mouse model.
Kunstfeld R; Wickenhauser G; Michaelis U; Teifel M; Umek W; Naujoks K; Wolff K; Petzelbauer P
J Invest Dermatol; 2003 Mar; 120(3):476-82. PubMed ID: 12603862
[TBL] [Abstract][Full Text] [Related]
15. The drug loading, cytotoxicty and tumor vascular targeting characteristics of magnetite in magnetic drug targeting.
Dandamudi S; Campbell RB
Biomaterials; 2007 Nov; 28(31):4673-83. PubMed ID: 17688940
[TBL] [Abstract][Full Text] [Related]
16. Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies.
Horsman MR; Siemann DW
Cancer Res; 2006 Dec; 66(24):11520-39. PubMed ID: 17178843
[TBL] [Abstract][Full Text] [Related]
17. Nanovesicular Formulations for Cancer Gene Therapy.
Tavano L; Mazzotta E; Muzzalupo R
Curr Pharm Des; 2017; 23(35):5327-5335. PubMed ID: 28741454
[TBL] [Abstract][Full Text] [Related]
18. Identification of novel drug targets for angiostatic cancer therapy; it takes two to tango.
Thijssen VL; van Beijnum JR; Mayo KH; Griffioen AW
Curr Pharm Des; 2007; 13(35):3576-83. PubMed ID: 18220794
[TBL] [Abstract][Full Text] [Related]
19. Effect of the surface charge of liposomes on their uptake by angiogenic tumor vessels.
Krasnici S; Werner A; Eichhorn ME; Schmitt-Sody M; Pahernik SA; Sauer B; Schulze B; Teifel M; Michaelis U; Naujoks K; Dellian M
Int J Cancer; 2003 Jul; 105(4):561-7. PubMed ID: 12712451
[TBL] [Abstract][Full Text] [Related]
20. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy.
Pastorino F; Brignole C; Marimpietri D; Cilli M; Gambini C; Ribatti D; Longhi R; Allen TM; Corti A; Ponzoni M
Cancer Res; 2003 Nov; 63(21):7400-9. PubMed ID: 14612539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
